Company / Capital Expenditures
Ernexa Therapeutics Inc. Capital Expenditures History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$369.0K
FY2025
5-year range
$19.0K / $966.0K
FY2021-FY2025
Trend
+1842.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +1842% YoY in FY2025, a notable deviation from the 9-year average annual change of +192%.
Based on SEC 10-K filings.
$369,000 in FY2025 with a 10-year CAGR of -7.8%.
Improved from $297,000 to $369,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -17.5%
- 10-Year CAGR
- -7.8%
Key checks
Key Insights
- 5-year CAGR of -17.5%, indicating a declining trend.
- In FY2025, capital expenditures increased 1842.1% year-over-year.
- Peak capital expenditures was recorded in FY2014.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $369.0K | +1842.1% |
| FY2024 | $19.0K | -93.6% |
| FY2023 | $297.0K | -69.3% |
| FY2020 | $966.0K | +49.1% |
| FY2019 | $648.0K | -11.0% |
| FY2018 | $728.0K | +70.5% |
| FY2017 | $427.0K | -56.9% |
| FY2016 | $991.0K | +18.7% |
| FY2015 | $835.0K | -24.7% |
| FY2014 | $1.1M | -9.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026